Amgen and Sanofi hit back on PCSK9 price criticisms

18 August 2016
2019_biotech_test_vial_discovery_big

The makers of two cholesterol-lowering drugs have responded to a report which said that their products were not cost-effective and called for their US price to be cut by at least 68%.

An article in the Journal of the American Medical Association (JAMA) looked at the cost-effectiveness of recently-approved proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for lowering low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD).

The drugs analyzed were Repatha (evolocumab), marketed by US biotech major Amgen (Nasdaq: AMGN), and Praluent (alirocumab), from French pharma Sanofi (Euronext: SAN) and the USA’s Regeneron (Nasdaq: REGN).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology